Parallax Volatility Advisers’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-7,500
| Closed | -$1.05M | – | 1640 |
|
|
2025
Q3 | $1.05M | Buy |
+7,500
| New | +$1.01M | ﹤0.01% | 1089 |
|
|
2023
Q4 | – | Sell |
-2,800
| Closed | -$720K | – | 2181 |
|
|
2023
Q3 | $720K | Hold |
2,800
| – | – | ﹤0.01% | 1494 |
|
|
2023
Q2 | $798K | Sell |
2,800
-9,400
| -77% | -$2.8M | ﹤0.01% | 1494 |
|
|
2023
Q1 | $3.39M | Sell |
12,200
-91,900
| -88% | -$25.4M | 0.01% | 1021 |
|
|
2022
Q4 | $28.8M | Sell |
104,100
-13,100
| -11% | -$3.7M | 0.04% | 414 |
|
|
2022
Q3 | $31.3M | Buy |
117,200
+109,900
| +1,505% | +$23.3M | 0.05% | 400 |
|
|
2022
Q2 | $1.49M | Buy |
7,300
+6,800
| +1,360% | +$1.39M | ﹤0.01% | 1477 |
|
|
2022
Q1 | $105K | Sell |
500
-82,300
| -99% | -$17.9M | ﹤0.01% | 2344 |
|
|
2021
Q4 | $19.9M | Sell |
82,800
-10,500
| -11% | -$2.7M | 0.02% | 607 |
|
|
2021
Q3 | $26.4M | Buy |
93,300
+30,700
| +49% | +$10.1M | 0.02% | 564 |
|
|
2021
Q2 | $21.7M | Buy |
+62,600
| New | +$19M | 0.02% | 599 |
|
|
2021
Q1 | – | Sell |
-49,900
| Closed | -$12.2M | – | 3254 |
|
|
2020
Q4 | $12.2M | Buy |
49,900
+15,300
| +44% | +$3.95M | 0.01% | 984 |
|
|
2020
Q3 | $9.81M | Buy |
34,600
+21,400
| +162% | +$5.97M | 0.01% | 1010 |
|
|
2020
Q2 | $3.53M | Buy |
13,200
+11,900
| +915% | +$3.58M | ﹤0.01% | 1222 |
|
|
2020
Q1 | $411K | Sell |
1,300
-48,400
| -97% | -$14.7M | ﹤0.01% | 1795 |
|
|
2019
Q4 | $14.7M | Buy |
49,700
+9,700
| +24% | +$2.69M | 0.02% | 520 |
|
|
2019
Q3 | $9.31M | Sell |
40,000
-81,600
| -67% | -$19M | 0.01% | 617 |
|
|
2019
Q2 | $28.4M | Sell |
121,600
-55,000
| -31% | -$12.7M | 0.03% | 271 |
|
|
2019
Q1 | $41.7M | Sell |
176,600
-71,300
| -29% | -$22.5M | 0.05% | 189 |
|
|
2018
Q4 | $74.6M | Buy |
247,900
+216,700
| +695% | +$69.2M | 0.1% | 152 |
|
|
2018
Q3 | $11M | Buy |
+31,200
| New | +$10.7M | 0.01% | 440 |
|
|
2017
Q1 | – | Sell |
-56,000
| Closed | -$15.9M | – | 3554 |
|
|
2016
Q4 | $15.9M | Hold |
56,000
| – | – | 0.03% | 328 |
|
|
2016
Q3 | $17.5M | Buy |
56,000
+55,300
| +7,900% | +$16.4M | 0.03% | 302 |
|
|
2016
Q2 | $169K | Sell |
700
-29,300
| -98% | -$7.72M | ﹤0.01% | 1852 |
|
|
2016
Q1 | $7.81M | Buy |
30,000
+24,800
| +477% | +$6.55M | 0.02% | 431 |
|
|
2015
Q4 | $1.59M | Buy |
5,200
+200
| +4% | +$57.5K | ﹤0.01% | 1091 |
|
|
2015
Q3 | $1.46M | Buy |
+5,000
| New | +$1.65M | ﹤0.01% | 1148 |
|
|
2014
Q3 | – | Sell |
-21,600
| Closed | -$6.81M | – | 4136 |
|
|
2014
Q2 | $6.81M | Sell |
21,600
-7,000
| -24% | -$2.11M | 0.03% | 400 |
|
|
2014
Q1 | $8.75M | Buy |
28,600
+15,200
| +113% | +$4.82M | 0.05% | 275 |
|
|
2013
Q4 | $3.75M | Sell |
13,400
-11,000
| -45% | -$2.85M | 0.02% | 504 |
|
|
2013
Q3 | $5.88M | Sell |
24,400
-20,000
| -45% | -$4.48M | 0.03% | 336 |
|
|
2013
Q2 | $9.55M | Buy |
+44,400
| New | +$9.49M | 0.04% | 273 |
|
Other funds holding BIIB
Parallax Volatility Advisers's BIIB Position: Q2 2026 in Review
Parallax Volatility Advisers increased its Biogen (BIIB) stake by 36% in Q2 2026, buying an estimated $115K and bringing the position to 2,291 shares worth $495K. The position accounts for ﹤0.01% of the portfolio, ranked #1116.
Parallax Volatility Advisers first reported a position in BIIB in Q4 2013 and has held it in 38 quarters since. The position peaked at $46.6M in Q4 2021. 1,043 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.
- Parallax Volatility Advisers held 2,291 shares of Biogen worth $495K as of Q2 2026.
- Parallax Volatility Advisers bought 602 Biogen shares in Q2 2026, an estimated $115K.
- Biogen made up ﹤0.01% of Parallax Volatility Advisers's portfolio in Q2 2026, its #1116 holding.
- Parallax Volatility Advisers first reported a position in Biogen in Q4 2013 and has held it in 38 quarters since.
- Parallax Volatility Advisers's Biogen position peaked at $46.6M in Q4 2021.
- 1,043 funds tracked by Wall St. Rank held Biogen as of Q2 2026.
Based on Parallax Volatility Advisers's 13F filing for Q2 2026, filed 14 Aug 2026.